AIM ImmunoTech News - August 31, 2026
🔴 AIM ImmunoTech is trading 10.87% down today after patent-driven interest reversed intraday
AIM ImmunoTech is trading 10.87% down at $0.23 after an intraday reversal from initial buying sparked by its August 31, 2026, announcement of a broad U.S....
🔴 AIM ImmunoTech is trading 6.4% down today after intraday reversal
AIM ImmunoTech is trading at $0.24 (-6.42%) after an intraday reversal following initial buying on its patent announcement. - The company announced a broad...
AIM ImmunoTech's New Cancer Patent Sparks a 34% Rally — But Can a Sub-$10 Million Company Cash In on a $32 Billion Drug Market?
Shares of AIM ImmunoTech surged 34.3% to $0.35 on an otherwise red-tape Monday after the company announced the U.S. Patent and Trademark Office granted it...
🟢 AIM ImmunoTech is trading 34.29% up today after USPTO grants Ampligen-pembrolizumab patent
AIM ImmunoTech is trading 34.29% up now at $0.35 after announcing on August 31, 2026, that the USPTO granted a patent covering Ampligen combined with...
🟢 AIM ImmunoTech is trading 25.66% up today in pre-market
AIM ImmunoTech is trading at $0.32, +25.66%, after rising from the August 28 close of $0.26. • No fresh August 31 company-specific announcement was...